These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

782 related articles for article (PubMed ID: 16156677)

  • 1. Alternatives to levodopa in the initial treatment of early Parkinson's disease.
    Lees A
    Drugs Aging; 2005; 22(9):731-40. PubMed ID: 16156677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors.
    Chen JJ; Fernandez HH
    Drugs Aging; 2007; 24(8):663-80. PubMed ID: 17702535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease.
    Caslake R; Macleod A; Ives N; Stowe R; Counsell C
    Cochrane Database Syst Rev; 2009 Oct; (4):CD006661. PubMed ID: 19821381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.
    Deleu D; Northway MG; Hanssens Y
    Clin Pharmacokinet; 2002; 41(4):261-309. PubMed ID: 11978145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
    Oertel W; Schulz JB
    J Neurochem; 2016 Oct; 139 Suppl 1():325-337. PubMed ID: 27577098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
    Jankovic J; Stacy M
    CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.
    Pahwa R
    J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):4-10. PubMed ID: 17948613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Parkinson's disease: what is the best approach to treatment.
    Hristova AH; Koller WC
    Drugs Aging; 2000 Sep; 17(3):165-81. PubMed ID: 11043817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial.
    Gray R; Patel S; Ives N; Rick C; Woolley R; Muzerengi S; Gray A; Jenkinson C; McIntosh E; Wheatley K; Williams A; Clarke CE;
    JAMA Neurol; 2022 Feb; 79(2):131-140. PubMed ID: 34962574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
    Fernandez HH; Chen JJ
    Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis.
    Binde CD; Tvete IF; Gåsemyr JI; Natvig B; Klemp M
    Eur J Clin Pharmacol; 2020 Dec; 76(12):1731-1743. PubMed ID: 32710141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-dopaminergic treatments for motor control in Parkinson's disease.
    Fox SH
    Drugs; 2013 Sep; 73(13):1405-15. PubMed ID: 23917951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role of selective monoamine oxidase B inhibitors in the therapeutic strategy of Parkinson's disease in the neurology clinics of Tirgu Mures County Emergency Clinical Hospital].
    Szász JA; Constantin V; Fazakas PA; Blényesi E; Grieb LG; Balla A; Sárig M; Szegedi K; Bartha EN; Szatmári S
    Orv Hetil; 2017 Dec; 158(51):2023-2028. PubMed ID: 29250969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapy for Parkinson's disease.
    Chen JJ; Swope DM
    Pharmacotherapy; 2007 Dec; 27(12 Pt 2):161S-173S. PubMed ID: 18041936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early pharmacologic treatment in Parkinson's disease.
    Hauser RA
    Am J Manag Care; 2010 Mar; 16 Suppl Implications():S100-7. PubMed ID: 20297870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoamine oxidase B inhibitors for early Parkinson's disease.
    Macleod AD; Counsell CE; Ives N; Stowe R
    Cochrane Database Syst Rev; 2005 Jul; 2005(3):CD004898. PubMed ID: 16034956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.
    Stowe R; Ives N; Clarke CE; Deane K; ; Wheatley K; Gray R; Handley K; Furmston A
    Cochrane Database Syst Rev; 2010 Jul; (7):CD007166. PubMed ID: 20614454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Henchcliffe C; Schumacher HC; Burgut FT
    Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Strategies in Early Parkinson's Disease.
    Marsili L; Marconi R; Colosimo C
    Int Rev Neurobiol; 2017; 132():345-360. PubMed ID: 28554414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.